scholarly article | Q13442814 |
P356 | DOI | 10.1016/S0168-8278(94)80092-8 |
P698 | PubMed publication ID | 7814794 |
P2093 | author name string | Burroughs AK | |
McCormick PA | |||
McIntyre N | |||
Scheuer PJ | |||
Epstein O | |||
Scott F | |||
P2860 | cites work | A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 |
Effect of stanozolol on itching in primary biliary cirrhosis | Q34166986 | ||
Opioid peptides and primary biliary cirrhosis | Q35706319 | ||
Immunosupressive therapy for primary biliary cirrhosis | Q36767051 | ||
Classification of chronic viral hepatitis: a need for reassessment | Q37032966 | ||
Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis | Q39642410 | ||
Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions | Q40344888 | ||
Thalidomide-induced peripheral neuropathy. A prospective clinical, neurophysiological and pharmacogenetic evaluation | Q42205727 | ||
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus | Q42259263 | ||
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. | Q44573504 | ||
Treatment of erythema nodosum leprosum with thalidomide. | Q53993902 | ||
Thalidomide in actinic prurigo | Q56785080 | ||
Thalidomide for the treatment of chronic graft-versus-host disease | Q68075890 | ||
A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis | Q68505504 | ||
Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial | Q69357047 | ||
A pilot, double-blind, controlled 1-year trial of prednisolone treatment in primary biliary cirrhosis: hepatic improvement but greater bone loss | Q69721905 | ||
Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation | Q69910910 | ||
Thalidomide for graft-versus-host disease | Q69926191 | ||
Primary biliary cirrhosis is a dry gland syndrome with features of chronic graft-versus-host disease | Q72424956 | ||
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies | Q79447470 | ||
Thalidomide in hyperalgic pharyngeal ulceration of AIDS | Q93509771 | ||
The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies | Q94293605 | ||
P433 | issue | 4 | |
P921 | main subject | placebo | Q269829 |
primary biliary cholangitis | Q1072420 | ||
P304 | page(s) | 496-499 | |
P577 | publication date | 1994-10-01 | |
P1433 | published in | Journal of Hepatology | Q15724402 |
P1476 | title | Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study. | |
P478 | volume | 21 |
Q46509129 | A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue |
Q33591450 | Bile acid abnormalities in cholestatic liver diseases |
Q37618589 | Diagnosis and Management of Chronic Pruritus: An Expert Consensus Review |
Q42590864 | Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid |
Q34936778 | Evolving new therapies of autoimmune hepatitis |
Q35960781 | Management of primary biliary cirrhosis and autoimmune cholangitis |
Q37355843 | Natural history and management of primary biliary cirrhosis |
Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
Q24186852 | Pharmacological treatments for primary biliary cirrhosis: a network meta-analysis |
Q21202919 | Primary biliary cirrhosis |
Q56854243 | Primary biliary cirrhosis |
Q26853649 | Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy |
Q32111479 | Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing |
Q55333522 | Update on pharmacotherapies for cholestatic liver disease. |
Search more.